#United States #Indianapolis #Roche Diagnostics #cobas c703 #cobas ISE neo

Roche's New Era in Laboratory Efficiency

Roche Diagnostics has made a remarkable leap in laboratory automation with the recent FDA 510(k) clearance for its innovative analytical units, the cobas® c 703 and cobas® ISE neo. These ground-breaking devices are set to transform laboratory workflows and directly address the challenges of increasing testing demands and staffing shortages that are prevalent in today’s healthcare landscape.

A Closer Look at the cobas® c 703

The cobas® c 703 is engineered for high-throughput clinical chemistry testing, boasting a staggering capability of conducting up to 2,000 tests per hour. This unit significantly enhances workflow efficiency by integrating 70 reagent positions, allowing laboratories to run high-value tests continuously. The increased reagent capacity reduces the frequency of reloads, thus promoting uninterrupted operations. In addition, its monthly maintenance routine enhances both uptime and productivity, ensuring that laboratories can handle the modern challenges of high testing volumes.

Streamlined Operations with cobas® ISE neo

In addition to the c 703, Roche has introduced the cobas® ISE neo. With its ability to execute up to 1,800 tests per hour, this unit is designed to optimize ISE testing while also decreasing the requirement for manual labor through its automated maintenance features. The unit underscores Roche's commitment to improving laboratory efficiency, with a significant reduction in plastic waste per test due to more tests being obtainable from each reagent bottle.

Together, these two units form a formidable duo that not only automates traditionally manual processes but also augments the testing capacity and accelerates result turnaround times.

Addressing Modern Healthcare Challenges

Brad Moore, President and CEO of Roche Diagnostics North America, emphasized the company's focus on collaboration to mitigate staffing shortages and enhance testing capabilities. He stated, "Laboratories are the indispensable engine of modern healthcare, and Roche wants to partner in addressing staffing-shortage challenges and an ever-increasing demand for testing." This statement reflects Roche's commitment to innovation and support for healthcare settings in tackling the challenges they face today.

cobas® pro Integrated Solutions

The new analytical units are part of the cobas® pro integrated solutions platform, a modular system introduced in the U.S. in 2020 aimed at meeting diverse clinical chemistry and immunochemistry testing needs efficiently. Features such as intelligent sample routing and rapid assay incubation times are designed to streamline laboratory processes and enhance the overall efficiency of testing. Notably, the cobas® SonicWash feature ensures the integrity of samples through ultrasonic probe cleaning.

Roche's focus on sustainability is evident, as they have achieved a significant reduction in sample volume and plastic waste per test compared to previous generations of their systems. All these enhancements make Roche’s latest devices not only efficient but also environmentally conscientious.

Roche’s Heritage in Diagnostics

Founded in Basel, Switzerland in 1896, Roche has evolved into the world’s leading biotechnology company, specializing in in-vitro diagnostics. The firm prides itself on scientific excellence and innovation aimed at improving patient outcomes. Roche's commitment to sustainability further highlights its role in the healthcare community, transforming how diagnostics are approached to align with modern health technologies and ecological standards.

With over 4,000 cobas® analyzers installed across the U.S., Roche continues to solidify its position as a leader in the diagnostics market. The company will remain focused on its mission to deliver transformative diagnostic solutions supporting timely clinical decision-making.

To learn more about Roche and its product lines, visit www.roche.com.